Tradecamide

Tradecamide

SCHEMBL9157947

CN(C)C(=O)CCCCCCCCCCCCO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
GPR84 Q9NQS5 1/20 0.50
FFAR1 O14842 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
CHRNB2 P17787 1/20 0.48
CHRNB4 P30926 1/20 0.48
CHRNA4 P43681 1/20 0.48
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTT P42858 1/20 0.40
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
KDM4A O75164 8/20 0.38
KDM4C Q9H3R0 8/20 0.38
KDM5A P29375 1/20 0.38
KDM7A Q6ZMT4 1/20 0.38
PHF8 Q9UPP1 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
LMNA P02545 2/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9353528 1.00 ALDH1A1 (0.58) ALDH1A1GPR84FFAR1FFAR4CHRNB2
SCHEMBL9162411 1.00 ALDH1A1 (0.58) ALDH1A1GPR84FFAR1FFAR4CHRNB2
SCHEMBL9160212 1.00 ALDH1A1 (0.58) ALDH1A1GPR84FFAR1FFAR4CHRNB2
SCHEMBL9432308 1.00 ALDH1A1 (0.58) ALDH1A1GPR84FFAR1FFAR4CHRNB2
SCHEMBL9353551 1.00 ALDH1A1 (0.58) ALDH1A1GPR84FFAR1FFAR4CHRNB2
SCHEMBL16945134 1.00 ALDH1A1 (0.58) ALDH1A1GPR84FFAR1FFAR4CHRNB2
SCHEMBL9162783 1.00 ALDH1A1 (0.58) ALDH1A1GPR84FFAR1FFAR4CHRNB2
SCHEMBL1049266 0.97 ALDH1A1 (0.61) ALDH1A1GPR84FFAR1FFAR4CHRNB2
SCHEMBL96642 0.90
SCHEMBL3189950 0.89 ALDH1A1 (0.70) ALDH1A1CHRNB2CHRNB4CHRNA4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0413006-B1 HYDROXYALKANE CARBOXYLIC ACID DERIVATES AND THEIR USE SCHERING AG (DE) 1994-10-19 EP claimed
EP-0612719-A1 Hydroxyalkanecarboxylic acid derivatives SCHERING AKTIENGESELLSCHAFT (DE) 1994-08-31 EP claimed
EP-0571062-A1 Hydroxyalkylcarboxylic acid derivatives, their preparation and use SCHERING AKTIENGESELLSCHAFT (DE) 1993-11-24 EP claimed
US-5089175-A Treatment of disorders of skin and mucous membranes SCHERING AKTIENGESELLSCHAFT (DE) 1992-02-18 US claimed
EP-0413006-A1 HYDROXYALKANE CARBOXYLIC ACID DERIVATES AND THEIR USE. SCHERING AG (DE) 1991-02-20 EP claimed
WO-1990009373-A1 HYDROXYALKANE CARBOXYLIC ACID DERIVATES, THEIR MANUFACTURE AND USE SCHERING AKTIENGESELLSCHAFT (DE) 1990-08-23 WO claimed
EP-2841109-B1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA AS (DK) 2026-04-15 EP disclosed
WO-2025129358-A1 STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES INTELGENX CORP. (CA) 2025-06-26 WO disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 EP disclosed
CN-114605329-B Substituted indazole carboxamides or substituted azaindazole carboxamides FLT3 inhibitors and uses thereof 河南中医药大学 2024-01-26 CN disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 US disclosed
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2023-04-20 US disclosed
EP-0413006-B1 HYDROXYALKANE CARBOXYLIC ACID DERIVATES AND THEIR USE SCHERING AG (DE) 1994-10-19 EP disclosed
EP-0612719-A1 Hydroxyalkanecarboxylic acid derivatives SCHERING AKTIENGESELLSCHAFT (DE) 1994-08-31 EP disclosed
EP-0571062-A1 Hydroxyalkylcarboxylic acid derivatives, their preparation and use SCHERING AKTIENGESELLSCHAFT (DE) 1993-11-24 EP disclosed
WO-1993022278-A1 PROCESS FOR PRODUCING HYDROXYALKANE CARBOXYLIC ACID AMIDES SCHERING AKTIENGESELLSCHAFT (DE) 1993-11-11 WO disclosed
US-5089175-A Treatment of disorders of skin and mucous membranes SCHERING AKTIENGESELLSCHAFT (DE) 1992-02-18 US disclosed
EP-0413006-A1 HYDROXYALKANE CARBOXYLIC ACID DERIVATES AND THEIR USE. SCHERING AG (DE) 1991-02-20 EP disclosed
WO-1990009373-A1 HYDROXYALKANE CARBOXYLIC ACID DERIVATES, THEIR MANUFACTURE AND USE SCHERING AKTIENGESELLSCHAFT (DE) 1990-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 ALDH1A1 1053/4885GPR84 1029/4885FFAR1 1930/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 ALDH1A1 72/4885GPR84 2749/4885FFAR1 1513/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 ALDH1A1 72/4885GPR84 2749/4885FFAR1 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.